NUELIFE HEALTH SYSTEM, LLC
NUELIFE HEALTH SYSTEM, LLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at NUELIFE HEALTH SYSTEM, LLC.
NUELIFE HEALTH SYSTEM, LLC is a company.
Key people at NUELIFE HEALTH SYSTEM, LLC.
Nue Life Health (also referred to as NueLife Health) is a telemedicine startup providing at-home ketamine therapy and psychedelic-assisted mental wellness solutions for conditions like depression, anxiety, and PTSD.[1][2][3] It serves patients nationwide through a digital platform combining treatments, AI-driven personalization, music therapy, and community support, guided by licensed professionals, with operations in states like California, Texas, and Florida.[1][2][3] The company has achieved strong growth, including $2.11M in annual revenue growth, a 70.4% increase in patient signups, and $28.2M in total funding, while addressing accessibility barriers via financing partnerships.[1][3]
Nue Life Health emerged as a "psychedelics-meets-tech" platform, raising $3.3M in 2021 to develop its next-generation mental wellness solution.[2] Founded by CEO Juan Pablo Cappello and co-founder/CTO Demian Bellumio, the company is headquartered in Miami Beach, Florida, starting operations in California, Texas, and Florida with plans for U.S. expansion.[2][3] The idea stemmed from research on ketamine as a fast-acting antidepressant and studies from Johns Hopkins and Imperial College on psychedelics like MDMA and psilocybin, integrated with a knowledge graph database and AI for holistic, personalized care.[2] Key milestones include a $1.9M financing round in 2023, app expansion to all ketamine patients, and appointing Dr. Drummond as CMO.[3]
Nue Life rides the wave of psychedelic medicine and telemedicine growth, capitalizing on ketamine's FDA-recognized efficacy and emerging research on psychedelics amid a mental health crisis.[2] Timing aligns with regulatory shifts and public listings of peers like MindMed and ATAI, plus post-pandemic demand for remote care.[2] Market forces favoring it include insurance limitations creating financing needs (addressed via partnerships) and AI/tech integration for scalable personalization in a $18.9M revenue-generating firm with 129 employees.[1][3] It influences the ecosystem by normalizing at-home psychedelic therapies, expanding access, and blending biotech with digital health.
Nue Life is poised for nationwide scaling, leveraging its funding ($28.2M total) and tech stack to capture more of the mental health market amid rising psychedelic acceptance.[2][3] Trends like AI diagnostics, regulatory approvals for MDMA/psilocybin, and financing innovations will propel growth, though patient complaints highlight needs for better service retention post-2023 ownership change.[6] Its influence may evolve toward enterprise tools and broader therapy integration, solidifying its role in transforming accessible mental wellness from a startup innovator to ecosystem leader—echoing its founding mission to catalyze lasting change through psychedelics and tech.[2][4]
Key people at NUELIFE HEALTH SYSTEM, LLC.
